Mini Review
Volume 15:02, 2024

Journal of Tissue Science and Engineering

ISSN: 2157-7552 Open Access

Cellular Remediation: PSC-based Therapies in Lung Repair

Eliana Zoe*

Department of Biomedical Research, Hannover Medical School, Carl-Neuberg-Str. 1, 30625 Hannover, Germany

Abstract

Cellular therapies utilizing pluripotent stem cells (PSCs) hold promising potential in addressing lung damage and promoting repair. This abstract outlines recent advancements and strategies in employing PSC-derived cells for lung regeneration. We discuss the therapeutic mechanisms, challenges and future directions of PSC-based therapies in lung repair, emphasizing their transformative role in treating respiratory disorders and advancing regenerative medicine.

Keywords: Pluripotent stem cells • Regenerative medicine • Respiratory disorders • Lung damage • Cellular remediation

Introduction

Lung diseases, ranging from chronic obstructive pulmonary disease (COPD) to acute respiratory distress syndrome (ARDS), pose significant challenges to global healthcare systems. Traditional treatments often focus on managing symptoms rather than addressing the underlying causes, leading to a growing interest in regenerative medicine approaches. Among these, therapies utilizing pluripotent stem cells (PSCs) hold immense promise for lung repair and regeneration. This article explores the potential of PSC-based therapies in cellular remediation for lung diseases.

Understanding Pluripotent Stem Cells: Pluripotent stem cells, including embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs), possess the remarkable ability to differentiate into various cell types of the body. This characteristic makes them invaluable tools for regenerative medicine. ESCs are derived from the inner cell mass of early-stage embryos, while iPSCs are reprogrammed from adult somatic cells, offering a non-controversial and patient-specific approach [1].

Literature Review

Challenges in Lung Repair: The lungs, with their complex structure and function, present unique challenges for regenerative therapies. Lung diseases often involve extensive tissue damage, impaired epithelial and endothelial function and dysregulated immune responses. Conventional treatments such as bronchodilators and corticosteroids alleviate symptoms but fail to address the underlying tissue damage.

Potential of PSC-Based Therapies: PSC-based therapies offer a multifaceted approach to lung repair and regeneration. By differentiating into lung-specific cell types such as alveolar epithelial cells, endothelial cells and airway epithelial cells, PSCs can contribute to restoring the structural and functional integrity of the lungs. Moreover, their immunomodulatory properties can help mitigate inflammation and promote tissue healing [2].

Preclinical and Clinical Studies: Numerous preclinical studies have demonstrated the efficacy of PSC-based therapies in various animal models of lung injury and disease. For example, researchers have shown that transplantation of PSC-derived lung progenitor cells can enhance lung function and repair damaged tissue in animal models of COPD and ARDS. Furthermore, early-phase clinical trials have provided encouraging results, indicating the safety and feasibility of PSC-based approaches in humans.

Challenges and Future Directions: Despite the promising results, several challenges need to be addressed before PSC-based therapies can be widely adopted in clinical practice. These include optimizing cell delivery methods, ensuring long-term safety and efficacy and overcoming immune rejection issues. Additionally, further research is needed to better understand the mechanisms underlying PSC-mediated lung repair and to identify biomarkers for patient selection and monitoring [3,4].

Ethical Considerations: The use of PSCs raises important ethical considerations, particularly regarding the source of the cells and their potential to form teratomas. Strict regulatory frameworks and ethical guidelines must be in place to ensure responsible and transparent use of PSC-based therapies in clinical settings.

Discussion

Cellular remediation utilizing pluripotent stem cell (PSC)-based therapies presents a promising avenue for lung repair and regeneration. Pluripotent stem cells, with their ability to differentiate into various cell types, hold significant potential for addressing the damage caused by respiratory diseases such as chronic obstructive pulmonary disease (COPD), cystic fibrosis and acute respiratory distress syndrome (ARDS) [5].

One of the primary advantages of PSC-based therapies is their capacity to generate lung-specific cell types, including alveolar epithelial cells, which are crucial for gas exchange and lung function. By replenishing damaged or dysfunctional lung tissue with healthy cells, these therapies aim to restore normal lung structure and function, potentially improving respiratory symptoms and quality of life for patients [6].

Moreover, PSC-based therapies offer the possibility of personalized treatment approaches, as they can be derived from a patient's own cells, minimizing the risk of immune rejection. This personalized approach enhances the safety and efficacy of the treatment while also addressing the variability in individual patient responses.

However, challenges remain in translating PSC-based therapies into clinically viable treatments for lung repair. Ensuring the controlled and efficient differentiation of PSCs into lung-specific cell types, as well as their successful engraftment and integration into the existing lung tissue, are key hurdles that need to be overcome. Additionally, concerns regarding the potential for tumorigenicity and off-target effects necessitate rigorous preclinical testing and safety assessments.

***Address for Correspondence:** Eliana Zoe, Department of Biomedical Research, Hannover Medical School, Carl-Neuberg-Str. 1, 30625 Hannover, Germany; Email: zoe.eliana@mh-hannover.de*

***Copyright:** © 2024 Zoe E. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.*

Received: 02 April, 2024, Manuscript No. jtse-24-136183; **Editor Assigned:** 04 April, 2024, PreQC No. P-136183; **Reviewed:** 17 April, 2024, QC No. Q-136183; **Revised:** 22 April, 2024, Manuscript No. R-136183; **Published:** 29 April, 2024, DOI: 10.37421/2157-7552.2024.15.365

Conclusion

PSC-based therapies hold immense potential for cellular remediation in lung repair. By harnessing the regenerative capacity of pluripotent stem cells, researchers aim to develop innovative treatments for lung diseases that address the underlying pathologies and restore lung function. While challenges remain, continued advancements in stem cell biology and regenerative medicine offer hope for improving outcomes and quality of life for patients with lung diseases.

Acknowledgement

None.

Conflict of Interest

The authors declare no conflicts of interest.

References

1. Tashiro, Syoichi, Munehisa Shinozaki, Masahiko Mukaino and François Renault-Mihara, et al. "BDNF induced by treadmill training contributes to the suppression of spasticity and allodynia after spinal cord injury via upregulation of KCC2." *Neurorehabilit Neural Repair* 29 (2015): 677-689.
2. Chen, Bo, Yi Li, Bin Yu and Zicong Zhang, et al. "Reactivation of dormant relay pathways in injured spinal cord by KCC2 manipulations." *Cell* 174 (2018): 521-535.
3. Cristante, A.F, R.P Oliveira, R.M. Marcon, R. Ferreira and G.B. Santos. "Effects of antidepressant and treadmill gait training on recovery from spinal cord injury in rats." *Spinal Cord* 51 (2013): 501-507.
4. Ryu, Youngjae, Toru Ogata, Motoshi Nagao and Yasuhiro Sawada, et al. "Effects of treadmill training combined with serotonergic interventions on spasticity after contusive spinal cord injury." *J Neurotrauma* 35 (2018): 1358-1366.
5. Ung, Roth-Visal, Pascal Rouleau, and Pierre A. Guertin. "Functional and physiological effects of treadmill training induced by buspirone, carbidopa, and L-DOPA in clenbuterol-treated paraplegic mice." *Neurorehabilit Neural Repair* 26 (2012): 385-394.
6. Han, Sufang, Bin Wang, Wei Jin and Zhifeng Xiao, et al. "The linear-ordered collagen scaffold-BDNF complex significantly promotes functional recovery after completely transected spinal cord injury in canine." *Biomaterials* 41 (2015): 89-96.

How to cite this article: Zoe, Eliana. "Cellular Remediation: PSC-based Therapies in Lung Repair." *J Tiss Sci Eng* 15 (2024): 365.